Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
GP emigration from Ireland: an analysis of data from key destination countries.
BMC Health Serv Res
December 2024
RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Background: Ireland is experiencing a general practitioner (GP) workforce crisis, facing an ageing workforce, a growing population with increased life expectancy, and increased complexity of patients. The GP crisis threatens access to primary care in Ireland, as well as Ireland's aim to transform into a primary-care centred system of universal healthcare via the proposed "Sláintecare" healthcare reforms. The challenges faced are common to many countries as health systems seek to expand their medical workforce post-pandemic.
View Article and Find Full Text PDFFeasibility of implementing a decision aid for advanced cancer patients in a comprehensive cancer centers' outpatient setting: Valuable lessons learned.
Cancer Med
December 2024
Department of Medical Oncology, Medical Faculty Heidelberg, Section Translational Medical Ethics, National Center for Tumor Diseases, NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Background: Decision aids (DAs) have been proposed as tools to empower patients in decision-making. However, implementing DA for decisions in advanced cancer is challenging. This study focuses on perspectives of oncologists and other healthcare providers on the hindering and facilitating factors for implementing a customizable DA.
View Article and Find Full Text PDFEthics and Controversies in Animal Subjects Research and Impact on Clinical Decision-Making.
Anesthesiol Clin
December 2024
Research and Regulatory Affairs, Physicians Committee for Responsible Medicine (PCRM), 5100 Wisconsin Avenue, Northwest, Suite 400, Washington, DC 20016-4131, USA.
The harm inflicted on animals in biomedical research is justified, by those who accept it, by weighing it against proposed benefits for humans, but these are underappreciated and overstated, respectively. Clinical translation is poor due to interspecies and intraspecies differences, hindering the understanding of diseases and the development of safe and effective new human drugs. An urgent shift away from animal use toward human-focused new approach methodologies would enable human diversity to be factored more effectively into clinical practice.
View Article and Find Full Text PDFWithin each of 170 physicians, patients were randomized to access e-assist, an online program that aimed to increase colorectal cancer screening (CRCS), or control. Compliance was partial: of the experimental patients accessed e-assist while no controls were provided the access. Of interest are the average causal effect of assignment to treatment and the complier average causal effect as well as the variation of these causal effects across physicians.
View Article and Find Full Text PDFA phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
J Inherit Metab Dis
January 2025
Division of Medical Genetics and Genomics, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
Article Synopsis
- Pegunigalsidase alfa is a new enzyme replacement therapy for Fabry disease, showing a longer half-life and administered every 4 weeks instead of the typical 2-week schedule.
- The BRIGHT study involved 30 adult patients who switched from another ERT to pegunigalsidase alfa, revealing good safety results with mostly mild side effects and no new anti-drug antibodies.
- Although the treatment showed acceptable tolerance, more research is needed due to the small sample size, but it suggests that this 4-week regimen could be a viable new option for managing Fabry disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!